中年2型糖尿病患者的共病与衰弱
基于英国生物银行20566名40-72岁2型糖尿病患者的队列研究,中位随访8年,发现衰弱和共病普遍存在,且不同测量工具识别的人群差异大;各测量工具均与死亡、MACE、低血糖和跌倒风险增加相关,年龄影响绝对风险,但未发现与基线HbA1c关联。
要点
- 衰弱和共病在40-72岁2型糖尿病患者中普遍存在,42%被至少一种量表识别。
- 四种测量工具识别的人群重叠少,仅2.2%被全部四种量表识别。
- 各测量工具均与死亡、MACE、低血糖和跌倒风险增加相关。
核心结论
- 衰弱和共病评估应嵌入中老年2型糖尿病的常规管理。
- 识别方法及年龄等特征影响基线风险,应影响临床决策(如血糖控制)。
研究设计与样本
- 队列研究,基线2006-2010年,中位随访8年。
- 英国生物银行20566名40-72岁2型糖尿病患者,社区人群。
主要发现
- 衰弱和共病在40-72岁2型糖尿病患者中普遍存在。
- 42%被至少一种量表识别为衰弱或共病,2.2%被全部四种量表识别。
- 各测量工具均与全因、心血管和癌症死亡、MACE、低血糖和跌倒风险增加相关。
- 相同衰弱水平下,男性45、55、65岁5年死亡绝对风险分别为1.9%、4.4%、9.9%(衰弱表型)。
- 具有4种长期病症的男性45、55、65岁5年死亡绝对风险分别为1.3%、3.7%、7.8%。
关键数值与推荐
- 衰弱表型、衰弱指数、Charlson共病指数和长期病症数量四种测量工具。
- 结局包括全因、心血管和癌症死亡、MACE、低血糖住院、跌倒或骨折。
临床怎么用
- 在中老年2型糖尿病常规管理中应评估衰弱和共病。
- 识别方法和年龄影响基线风险,应据此调整临床决策如血糖控制目标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Context: Frailty and multimorbidity are common in type 2 diabetes, including in middle-aged people (<65 years). Clinical guidelines recommend adjustment of treatment targets in people with frailty or multimorbidity. However, guidelines do not specify how frailty/multimorbidity should be identified. It is not clear if recommendations should be applied to people with frailty/multimorbidity at younger ages. Objective: Assess prevalence and clinical implications of frailty/multimorbidity in middle- to older-aged people with type 2 diabetes using four different measures. Design: Cohort, baseline 2006-2010, median 8 years follow-up. Setting: Community Participants: UK Biobank participants (n=20,566) with type 2 diabetes aged 40-72 years. Exposures: Four measures of frailty (frailty phenotype and frailty index) and multimorbidity (Charlson Comorbidity index and numerical count of long-term conditions (LTCs)). Outcomes: Mortality (all-cause, cardiovascular- and cancer-related mortality), Major Adverse Cardiovascular Event (MACE), hospitalization with hypoglycaemia, fall or fracture. Results: Frailty and multimorbidity are prevalent in in people with type 2 diabetes from age 40-72. Individuals identified differed depending on which measure was used: 42% frail of multimorbid by at least one scale; 2.2% were identified by all four scales. Each measure was associated with increased risk of mortality (all-cause, cardiovascular, and cancer-related), MACE, hypoglycaemia and falls. The absolute risk of 5-year mortality was higher in older versus younger participants with a given level of frailty (e.g. 1.9%, 4.4%, and 9.9% in men aged, 45, 55, and 65, respectively, using frailty phenotype) or multimorbidity (e.g. 1.3%, 3.7%, and 7.8% in med with 4 long-term conditions aged 45, 55, and 65, respectively). No measure was associated with baseline HbA1c. For the frailty index, Charlson Comorbidity index, and LTC count, the relationship between HbA1c and mortality was consistent across all levels of frailty/multimorbidity. For the frailty phenotype, the relationship between HbA1c and mortality was steeper and more linear in frail compared with pre-frail or robust participants. Conclusion: Assessment of frailty/multimorbidity should be embedded within routine management of middle-aged and older people with type 2 diabetes. Method of identification as well as features such as age impact baseline risk and should influence clinical decisions (eg. glycaemic control).
引用
- Hanlon P, Jani B, Mair F, et al. Multimorbidity and frailty in middle-aged adults with type 2 diabetes mellitus. Ann Fam Med. 2022. PMID: 36857144. doi:10.1370/afm.20.s1.2910
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。